TipRanks
Advertisement
Advertisement

XNCR Stock Latest News

Xencor price target raised to $26 from $20 at BofA
The FlyXencor price target raised to $26 from $20 at BofA
21d ago
XNCR
Xencor price target raised to $35 from $27 at Barclays
PremiumThe Fly
Xencor price target raised to $35 from $27 at Barclays
1M ago
XNCR
Xencor price target raised to $21 from $14 at JPMorgan
PremiumThe Fly
Xencor price target raised to $21 from $14 at JPMorgan
1M ago
XNCR
3 AI ETFs With 70%+ Upside to Buy in September, According to Analysts
PremiumMarket News
3 AI ETFs With 70%+ Upside to Buy in September, According to Analysts
1M ago
AMD
TXG
Xencor price target raised to $46 from $40 at Raymond James
PremiumThe Fly
Xencor price target raised to $46 from $40 at Raymond James
1M ago
XNCR
Xencor Advances Dual-Antibody Cancer Trial, Keeping Investor Focus on XNCR
PremiumCompany AnnouncementsXencor Advances Dual-Antibody Cancer Trial, Keeping Investor Focus on XNCR
2M ago
XNCR
Analyst John Newman Reiterates Buy on Xencor, Citing Late-Stage XmAb Pipeline, Non-Dilutive Cash Inflows and Royalties, and Sets $38 Price Target
Premium
Ratings
Analyst John Newman Reiterates Buy on Xencor, Citing Late-Stage XmAb Pipeline, Non-Dilutive Cash Inflows and Royalties, and Sets $38 Price Target
2M ago
XNCR
Xencor price target raised to $30 from $26 at Wedbush
Premium
The Fly
Xencor price target raised to $30 from $26 at Wedbush
2M ago
XNCR
Xencor price target raised to $44 from $43 at Cantor Fitzgerald
PremiumThe Fly
Xencor price target raised to $44 from $43 at Cantor Fitzgerald
2M ago
XNCR
Xencor price target raised to $20 from $19 at RBC Capital
PremiumThe Fly
Xencor price target raised to $20 from $19 at RBC Capital
2M ago
XNCR
Xencor: Buy Rating Backed by XmAb819 Expansion and Immunology Pipeline Milestones Ahead of Key 2026–2027 Data Catalysts
PremiumRatings
Xencor: Buy Rating Backed by XmAb819 Expansion and Immunology Pipeline Milestones Ahead of Key 2026–2027 Data Catalysts
2M ago
XNCR
Xencor Earns Buy Rating as XmAb541 and XmAb808 Advance Toward Differentiated Solid-Tumor Franchise
PremiumRatings
Xencor Earns Buy Rating as XmAb541 and XmAb808 Advance Toward Differentiated Solid-Tumor Franchise
2M ago
XNCR
Xencor reports Q2 EPS (29c), consensus (84c)
PremiumThe FlyXencor reports Q2 EPS (29c), consensus (84c)
2M ago
XNCR
Xencor participates in a conference call with Cantor
Premium
The Fly
Xencor participates in a conference call with Cantor
2M ago
XNCR
Xencor’s XmAb412 Enters First-in-Human Testing: What Early-Stage Investors Should Watch
Premium
Company Announcements
Xencor’s XmAb412 Enters First-in-Human Testing: What Early-Stage Investors Should Watch
2M ago
XNCR
Xencor Expands Plamotamab Into Rheumatoid Arthritis: What Early Trial Progress Means for Investors
PremiumCompany Announcements
Xencor Expands Plamotamab Into Rheumatoid Arthritis: What Early Trial Progress Means for Investors
2M ago
XNCR
Xencor Inc. (XNCR) Q2 Earnings Cheat Sheet
PremiumPre-Earnings
Xencor Inc. (XNCR) Q2 Earnings Cheat Sheet
2M ago
XNCR
Xencor Secures Ultomiris Royalty Settlement Payment
PremiumCompany Announcements
Xencor Secures Ultomiris Royalty Settlement Payment
2M ago
8K
XNCR
Xencor to receive $105M from Alexion to resolve Ultomiris royalty matter
PremiumThe Fly
Xencor to receive $105M from Alexion to resolve Ultomiris royalty matter
2M ago
XNCR
Xencor price target lowered to $27 from $29 at Truist
PremiumThe FlyXencor price target lowered to $27 from $29 at Truist
3M ago
XNCR
Xencor Shareholders Approve Directors, Incentive Plan Amendments
Premium
Company Announcements
Xencor Shareholders Approve Directors, Incentive Plan Amendments
4M ago
8K
XNCR
Acting FDA head vows to block political interference, Endpoint News says
Premium
The Fly
Acting FDA head vows to block political interference, Endpoint News says
4M ago
AZN
BMY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >